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ABSTRACT 
The carcinogenic potential of  oxisuran, a synthetic immunosuppressive 
agent, was studied for 80 weeks and 104 weeks in mice and rats, respectively. 
Groups of  50 mice and 70 rats of  each sex received oxisuran at doses of 600, 
240, and 40 mg/kg/day as dietary admixtures over the entire experimental 
period. Adequate survival rates allowed accurate statistical analysis of  
diagnosed neoplasia. Increased susceptibility to tumor  development  was not  
clearly demonstrated.  In mice the only statistically significant increase in the 
incidence of  malignancy was lung carcinomas in high dose females (P<  0.05). 
However,  lung carcinoma incidence was significantly decreased in mid- and 
low-dose male mice when compared to spontaneous control  rates (P < 0.01). 
Although not  confirmed statistically, there was an increased incidence of 
lung carcinomas and liver cell adenomas in high dose male mice, and increased 
lymphoid tumors  in all female treated groups. In rats, the incidence of liver 
cell adenomas in high dose animals of  both sexes was increased, although 
confirmed statistically in males only (P < 0.01). In high dose females, 
significantly decreased incidences of  mammary fibroadenomas, pituitary 
chromophobe  adenomas, and thyroid parafollicular cell tumors  (P < 0.01) 
contr ibuted to an overall decrease in both benign tumors  and in the com- 
bined benign and malignant tumor  rates. 
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I NTRODUCTION 
Current concepts linking immunologic mechanisms to cancer would 
indicate that depressed immune responses increase susceptibility to the 
development of neoplasms. Thus, inhibition of tissue-mediated immune 
response in "nude" mice would result in increased tumor formation when 
maintained for almost 2 years under germ-free conditions [1]. Thomas 
and Burnet conceptualized the theory of immunologic surveillance and 
reasoned that malignancies elicit a protective immunologic reaction, possibly 
similar to the type that destroys grafts of foreign tissues [2,3]. Oxisuran has 
been characterized as a differential inhibitor of cell-mediated hypersensitivity 
that suppresses allograft immunity, without concomitant suppression of 
humoral antibody formation that may deprive the host of normal immuno- 
logical defenses [4,5]. This compound prolonged the survival of skin allo- 
graphs in mice and rats, but did not suppress the response of normal or 
grafted mice to an immunogen, sheep erythrocytes. Long-term carcinogenicity 
bioassays of oxisuran in rats and mice were undertaken to determine whether 
the compound would elicit tumorigenic potential. Increased susceptibility 
to cancer formation was not demonstrated unequivocally, and although 
other mechanisms cannot be excluded, the reduced incidence of certain 
tumor types in rats may be mediated through immunosuppression. 
Various mechanisms of tumor formation, and the immunogenic nature of 
various tumors in avariety of species may account for the increased tendency 
towards tumor formation in some instances and decreased in others [6]. 
MATERIALS AND METHODS 
Chemical 
Oxisuran, 2[(methylsulfinyl)acetyl]-pyridine (Fig. 1), is a non-hygro- 
scopic off-white crystalline material with a molecular weight of 183.2 and 
a melting point of 71--72°C; it is readily soluble in water, propylene glycol, 
and ethanol. 
Animals and housing 
Random bred, barrier raised albino CF1 mice and albino Wistar rats were 
supplied by Carworth Farms, New City, NY and Hilltop Caviary, Scottdale, 
PA, respectively. The animals were approximately 42 days of age at the 
initiation of study. These animal strains were selected based upon the wealth 





Fig. 1. Oxisuran: 2-[(methylsulfinyl)acetyl]-pyridine.  
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carcinogenesis bioassay program in 1967. The strains have been genetically 
stable with adequate survival rates at 80 weeks for mice and 104 weeks for 
rats, moderate  incidence of  spontaneous neoplasia, and low incidence of  
intercurrent pathology. 
Animals in substandard clinical condition were culled during a 2-week 
quarantine period. Rats selected for s tudy were housed individually in 
suspended stainless steel cages while groups of  3 mice were housed in plastic 
boxes with pressed hardwood bedding chips. Some male mice were sepacated 
into individual units as a result o f  aggressive behavior. The animals were 
maintained in clean rooms with controlled temperature (23 -+ 2°C) and 
relative humidi ty (40--60%), together with 18 fresh air exchanges and an 
l l - h  photoperiod.  The species were housed in separate animal rooms. Fresh 
water was supplied ad libitum. Animals were weighed once weekly for the 
initial 6 months  of  s tudy and once every 2 weeks thereafter. Food  con- 
sumption was measured weekly throughout  the entire experimental period. 
From these data, drug levels in diet were adjusted weekly to compensate for 
changes in mean body weight and food consumption.  Rats received 180 g 
of  drug-diet admixture weekly while mice were given 60 g quantities. 
All animals were observed at least once daily for evidence of overt toxicity. 
Complete physical examinations were performed pretest and monthly  there- 
after. Ophthalmic examinations were performed on all mice at pretest and 
at 28, 52, and 80 weeks and in rats at pretest,  and at 6, 12, 18, and 24 
months. Ten rats per sex group were sacrificed at 26 and 78 weeks. Clinical 
laboratory studies were conducted on rats sacrificed at 6, 18, and 24 months. 
These clinical and laboratory data, other  than those needed for carcinogenesis 
assessment, have no t  been included in this paper for the sake of brevity. 
Experimental groups 
Dose levels selected for these experiments were based upon an overall 
assessment of  effects encountered in previous acute, subacute, and long- 
term toxicology studies [7].  Groups of 50 mice and 70 rats of  each sex 
received oxisuran at 600, 240, and 40 mg/kg/day. The untreated control  
group consisted of  100 mice and 120 rats of each sex. 
Pathology studies 
Animals found dead or extremely debilitated were sacrificed for humane 
reasons and to minimize onset  of  autolytic changes in the event of  death. All 
animals were autopsied; those sacrificed in extremis were considered deaths 
for the purposes of  data analysis. In animals sacrificed terminally, absolute 
organ weights and organ to body  weight ratios were determined for gonads, 
liver, kidneys, prostate and uterus. In rats, thyroid and adrenal weights also 
were recorded. Following gross examinations, tissues and gross abnormalities 
from all animals were processed and evaluated microscopically. A blood 
smear was obtained from mice with suspected lymphoid tumors  in order to 
a t tempt  the classification of these neoplasia. 
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Method of tumor analysis 
All tumors noted upon gross examination were subjected to microscopic 
confirmation. The technique for statistical analysis has been described pre- 
viously [8] .  Briefly, the time of  onset of  all tumors was set when they were 
first noted in the in vivo phase. The onset of  internal, nonpalpable tumors 
was established at the time of  autopsy. The criteria for tumorigenic response 
was based on histotyping of  tumors, positive dose relationships, statistically 
significant differences in tumor rates, changes in onset, average onset, or 
latency, and the occurrence of  highly unusual or unexpected tumors. 
R E S U L T S  
Survival data for animals fed the various drug regimens are presented in 
Figs. 2 and 3 for mice and rats, respectively. Group survival rates in both 
mice {40--66%) and rats (29--52%) ensured adequate statistical power for 
tumor analysis. Reduced rat survival rates were influenced by the 26 week 
and 78 week interim sacrifice of  10 animals/sex group at each interval. The 
animals maintained satisfactory clinical condition throughout the studies. 
Clinical signs were primarily related to aggressive behavior of  male mice and 
aging changes in both species. In female rats, the incidence of  grossly palpable 
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Fig. 3. Probabi l i ty  o f  survival o f  ra ts  fed  ox isuran  for  104 weeks.  
mammary nodules in mid, low, and control groups appeared similar (29, 23, 
and 28%, respectively), but was apparently decreased in high dose females 
(13%). In female mice, mammary nodules were palpated in 10, 8, 10, and 9% 
of high, mid, and low dose animals and untreated controls, respectively. 
Body weight gain suppression at termination was apparent only in rats in 
the high and mid dose groups. 
No body, liver or kidney weight differences were noted in the various 
groups of mice (Table I). In male and female rats, absolute liver weight and 
liver/100 g body weight ratios were increased, as were the absolute and 
relative kidney weights at 104 weeks. 
HistopathologicaUy, the only non-neoplastic change associated with treat- 
ment in rots was a dose-related ground glass appearance of hepatocyte cyto- 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































DISTRIBUTION OF TUMOR TYPES IN MICE GIVEN OXISURAN ORALLY FOR 80 
WEEKS AND IN RATS FOR 104 WEEKS 
Organ/tumor type b'c Treatment groups a 
Males Females 
Oxisuran Oxisuran 
(600) (240) (40) (0) (600) (240) (40) (0) 
Mice 
Bone: 
Osteoma 0 1 2 2 3 4 6 6 
Liver: 
Adenoma 8 2 5 9 2 0 1 0 
Lung: 
Alveologenic 
adenocarcinoma 17 7** 5** 22 12" 7 9 18 
Mammary gland: 
Adenocarcinoma 0 0 0 1 4 6 5 11 
Uterus: 
Polyp . . . .  2 1 2 4 
General: 
Lymphoid tumor 8 8 9 19 22 21 19 30 
Animals with benign tumorsd, e 9 3 f 11 11 8 8 8 15 
Animals with malignant 22 13 14 42 33 31 32 54 
tumors 
Animals with tumors 26 16 18 48 34 35 36 60 
Rats 
Brain: 
Astrocytoma 1 0 0 4 0 0 0 1 
Liver: 
Adenoma 8** 1 0 2 7 3 2 4 
Lymph node: 
Hemangioma 0 0 0 4 0 0 0 1 
Mammary gland: 
Adenocarcinoma 0 0 0 0 4 4 3 6 
Fibroadenoma 0 0 0 0 3"* 12"* 14 29 
Pituitary: 
Adenoma 9 6 3* 21 8** 23 20 44 
Thyroid: 
Parafollicular ~ n  
Tumor 1 0 1 8 2"* 0 0 11 
Uterus: 
Polyp . . . .  10 7 5 9 
General: 
Lymphoid tumor  2 5 3 9 5 1 5 8 
Animals with benign tumors d'e 17 10 7* 32 26** 39 35 73 
Animals with malignant tumors 9 8 11 20 14 8 13 17 
Animals with tumors 25 16" 17" 48 33* 44 40 80 
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TABLE II (continued) 
aNumbers in parentheses indicate level of  drug in mg/kg/day; number of  animals/sex/group 
indicated in Table I. 
bOnly those tumors where a frequency of  4 or more per group are listed, although all 
tumors are included in the overall incidence values. 
Cprohability analysis by life-table technique; *P < 0.05 and **P < 0.01. 
dSome animals may have had more than 1 tumor. 
eChi square test used overall tumor incidence with a frequency > 0.20; values in the table 
with a superscript t indicate result of  exact probability test when incidence < 0.20. 
TABLE III 
EARLIEST ONSET AND AVERAGE LATENCY PERIOD OF COMMON TUMORS IN 
MICE FED OXISURAN ORALLY FOR 80 WEEKS AND IN RATS FOR 104 WEEKS a 
Tumor type Treatment groups 
Males Females 
Oxisuran Oxisuran 










66 69 77 70 69 80 76 73 
[76] [78] [79] [79] [78] [80] [80] [79] 
55 50 40 40 45 31 44 38 
[75] [74] [70] [68] [71] [70] [71] [72] 
77 80 80 47 72 -- 80 -- 
[80] [80] [80] [75] [76] -- [80] - -  
- -  - -  - -  49 72 32 48 48 
- -  - -  ' - -  [ 4 9 ]  [ 7 6 ]  [ 7 2 ]  [ 6 6 ]  [ 6 3 ]  
. . . .  8 0  8 0  8 0  5 8  
. . . . .  [80] [80] [80] [73] 
Rats 
Lymphoid 72 52 45 78 36 80 78 73 
[88] [76] [71] [93] [90] [80] [93] [97] 
Liver cell 71 102 -- 86 104 78 72 104 
Adenoma [97] [102] -- [95] [104] [95] [88] [104] 
Mammary . . . .  56 60 96 26 
Malignant . . . .  [87] [70] [101] [63] 
Benign . . . .  68 40 52 48 
. . . .  [94] [82] [87] [89] 
Pituitary 80 93 104 76 71 78 72 63 
Adenoma [101] [102] [104] [100] [93] [92] [94] [94] 
Uterine polyp . . . . .  69 78 78 78 
. . . .  [93] [100] [88] [101] 
aNumbers in parentheses indicate level of  drug in mg/kg/day; number of  animals per 
sex/group indicated in Table I; onset expressed as week when first tumor detected; 
average latency (in brackets) expressed as arithmetic mean of  onset weeks/tumor-bearing 
animals. 
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membranes as confirmed by electron microscopy not reported here. Centri- 
lobular hepatocytic hypertrophy was noted in male mice and may have been 
related to compound administration although no attempts for further 
characterization were applied. The frequencies of other non-neoplastic 
lesions were comparable and attributed to aging. 
In mice, the most common tumor types found were osteomas, alveologenic 
adenocarcinomas, and murine leukemia in both sexes, liver cell adenoi~as in 
males and mammary adenocarcinomas and uterine polyps in females (Table II). 
The incidence of lung carcinomas was significantly lower (P < 0.01) in mid 
and low dose males and significantly increased (P,~ 0.05) in high dose 
females. Although not confirmed statistically, lung carcinomas and liver cell 
adenomas (including hyperplastic nodules) in high dose males and lymphoid 
tumors in all female treated groups were increased in number in comparison 
with controls. No significant differences in onset and mean times of appear- 
ance were related to compound administration (Table III). 
The most common tumor types found in rats were benign liver cell tumors, 
chromophobe adenomas, and leukemia in both sexes and mammary adeno- 
carcinomas, mammary fibroadenomas, and uterine polyps in females 
(Table II). There was a significantly lower incidence of mammary fibro- 
adenoma, pituitary chromophobe adenoma, and thyroid parafollicular cell 
tumors in high dose females (P < 0.01), contributing to an overall decrease 
in both benign tumors and the combination of ben i~  and malignant classifi- 
cations. Pituitary adenomas also were significantly reduced in low dose males 
(P < 0.05). The incidence of liver cell adenomas was increased in high dose 
animals of both sexes, showing a statistically significant increase in males 
only (P < 0.01). Mean time of appearance and onset were unaffected by 
compound administration (Table III). 
DISCUSSION 
It is generally accepted that extended periods of immunosuppression 
increase the risk of either viral or chemical carcinogenesis [9--12], and favor 
the growth and metastatic potential of transplanted tumors [13]. The de- 
velopment of spontaneous neoplasms in humans in an immunosuppressed 
state also is enhanced [14]. 
The effects of long-term immunosuppression on the incidence of spon- 
taneously occurring tumors is much less definite and has not been studied in 
detail. Martinez demonstrated that thymectomy at birth resulted in a de- 
creased incidence of mammary carcinomas in mice [15]. Susceptibility to 
these ordinarily occurring tumors in mice may have been restored by the 
immunologic reconstitution of the animal with implants of thymic tissue 
[16]. Freund's adjuvant which enhances immunosuppressive activity, ad- 
ministered subsequent to 3-methylcholanthrene, and croton oil-immuno- 
suppression both enhanced the formation of malignant lymphomas [17--19]. 
Preliminary investigations with Imuran ® (azathioprine) suggested that 
mammary tumorigenesis stimulated by pituitary grafting was accelerated by 
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the immunosuppressive agent [20]. In long-term (14--16 months) investi- 
gations in female NZBXNZW mice with both azathioprine and ifosfamide 
(cyclophosphamide derivative), resulted in dose related increases in tumor 
frequency, predominantly lymphomas [21,22]. The sodium salt of azathio- 
prine was administered as daily intraperitoneal injections, resulting in signifi- 
cant immunodepression after 348 days of therapy [12]. No evidence of 
increased incidence of spontaneous malignancies was apparent after 2 years. 
Oxisuran has been shown to suppress tissue-mediated immune response 
by means of allograft rejection in rodents without causing suppression of 
humoral immune response [4,5]. Rodent carcinogenesis bioassays with 
oxisuran could provide further evidence of long-term effects on immuno- 
logical surveillance mechanisms. Increased susceptibility to tumor develop- 
ment was not clearly demonstrated following 80 weeks and 104 weeks of 
compound administration in mice and rats, respectively. Of particular 
interest, mammary fibroadenomas, pituitary chromophobe adenomas, and 
thyroid parafollicular cell tumors in high dose rats had significantly reduced 
incidence rates. 
Metabolism and pharmacokinetic investigations of oxisuran in 4 species 
(monkey, pig, dog, and rat) and in man, identified varying degrees of plasma 
levels of alcohol sulfoxides which contribute to the differential immuno- 
suppressive activity of the parent compound [23]. The observed species 
differences in immunosuppressive activity, as well as in biotransformation, 
may account for the increased tendency towards lung carcinoma induction 
in female mice, and decreased incidence of mammary fibroadenomas, 
pituitary chromophobe adenomas, and thyroid parafollicular cell tumors in 
female rats. These effects may also suggest sex differences, either by de- 
creased susceptibility or via metabolic transformation pathways. Also, 
compounds that prolong the survival of allografts commonly inhibit cellular 
proliferation by either crosslinking DNA or by preventing nucleic acid 
synthesis [7]. Variations in tissue proliferation rates could differentially 
affect the induction of neoplasia, depending on the age and sex of species, 
and the type, dose, and frequency of administration of the immunosup- 
pressive agent [19]. Tumor induction may also be influenced by factors 
other than immunosuppression, and it is possible that oxisuran may exert its 
tumorigenic potential by mechanisms other than changes in immunocom- 
petence. Nevertheless, the selective reduction of discrete types of tumors, 
such as mammary gland tumors, may indicate that the immune background 
may play a determining role in evoking spontaneous tumor rates in these 
organs. The increased lung tumor rates in mice and liver cell adenomas in 
rats could indicate that these represent target organs for the toxicity of this 
compound. 
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